APLM Apollomics
- 0.340
- -0.003-0.96%
- 0.342
- +0.002+0.68%
Apollomics News
Apollomics Announces ~$6M Private Placement Financing; Pursuant To The Terms Of The Subscription Agreements, Co Is Selling An Aggregate Of 19,166,666 Class A Ordinary Shares At A Price Of $0.30/Share
Apollomics Inc. (NASDAQ:APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced th
Apollomics Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co.
Apollomics Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co.
HC Wainwright & Co. : Maintain the Apollomics (APLM.US) rating, adjust from buy to buy rating, and adjust the target price from $5.00 to $2.00.
HC Wainwright & Co. : Maintain the Apollomics (APLM.US) rating, adjust from buy to buy rating, and adjust the target price from $5.00 to $2.00.
HC Wainwright & Co. Maintains Buy on Apollomics, Lowers Price Target to $2
HC Wainwright & Co. analyst Robert Burns maintains Apollomics (NASDAQ:APLM) with a Buy and lowers the price target from $5 to $2.
Maintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline Potential
Apollomics Inc Files For Mixed Shelf Of Up To $200M
Apollomics Inc Files For Mixed Shelf Of Up To $200M
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
Apollomics Price Target Cut to $6.50/Share From $11.00 by EF Hutton
Apollomics Price Target Cut to $6.50/Share From $11.00 by EF Hutton
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)
Apollomics Is Maintained at Buy by HC Wainwright & Co.
Apollomics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Apollomics, Lowers Price Target to $5
HC Wainwright & Co. analyst Robert Burns maintains Apollomics (NASDAQ:APLM) with a Buy and lowers the price target from $17 to $5.
Apollomics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 635.29% HC Wainwright & Co. $17 → $5 Maintains Buy 11/20/2023 2400% HC Wainwright & Co. → $17 R
Earnings Call Summary | Apollomics(APLM.US) Q4 2023 Earnings Conference
The following is a summary of the Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript:Financial Performance:Apollomics ended 2023 with cash and equivalents of $37.8 million.The company managed to
Apollomics GAAP EPS of -$2.32
Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
Apollomics FY EPS $(2.32) Up From $(8.44) YoY
Apollomics (NASDAQ:APLM) reported quarterly losses of $(2.32) per share. This is a 72.51 percent increase over losses of $(8.44) per share from the same period last year.
Press Release: Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results -- Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersApollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) share
Apollomics Appoints CFO
Apollomics Names Matthew Plunkett Finance Chief
By Chris Wack Apollomics has appointed Matthew Plunkett as its new finance chief. Plunkett most recently served as chief financial officer at Aeovian Pharmaceuticals. On Jan. 19, the biopharmaceuti
Analysis
Price Target
No Data
